# reload+after+2024-01-23 05:45:54.066574
address1§201 Haskins Way
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 695 0677
website§https://www.lyell.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
fullTimeEmployees§274
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Richard D. Klausner M.D.', 'age': 71, 'title': 'Founder & Executive Chairman', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 80000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Lynn  Seely M.D., Ph.D.', 'age': 64, 'title': 'President, CEO & Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 430689, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Charles W. Newton', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 1715968, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stephen J. Hill', 'age': 53, 'title': 'Chief Operating Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 1044726, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gary  Lee Ph.D.', 'age': 46, 'title': 'Chief Scientific Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 639912, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Elizabeth  Homans', 'age': 57, 'title': 'Consultant', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 1988982, 'exercisedValue': 0, 'unexercisedValue': 14029438}, {'maxAge': 1, 'name': 'Prof. Stanley R. Riddell M.D.', 'title': 'Founder & Scientific Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Crystal L. Mackall M.D.', 'age': 63, 'title': 'Founder & Scientific Advisor', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Nellie  Dillery', 'title': 'Director of Accounting', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ellen  Rose', 'title': 'Senior Vice President of Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§7
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.858
priceToSalesTrailing12Months§10.593422
currency§USD
dateShortInterest§1702598400
forwardEps§-0.86
pegRatio§0.26
exchange§NMS
quoteType§EQUITY
shortName§Lyell Immunopharma, Inc.
longName§Lyell Immunopharma, Inc.
firstTradeDateEpochUtc§1623936600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c5ad7970-8aa2-3c85-a7aa-1e907d8cc7ab
gmtOffSetMilliseconds§-18000000
targetHighPrice§9.0
targetLowPrice§4.0
targetMeanPrice§6.5
targetMedianPrice§6.5
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§16.411
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
